Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients

Caroline Protin; Florence Abravanel; Laurent Alric; Suzanne Tavitian; Lucie Obéric; Jacques Izopet; Guillaume Martin-Blondel; Loic Ysebaert

doi:10.1093/ofid/ofz345

Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients

Open Forum Infect Dis. 2019 Jul 28;6(9):ofz345. doi: 10.1093/ofid/ofz345. eCollection 2019 Sep.

Authors

Caroline Protin¹, Florence Abravanel^{2

3

4}, Laurent Alric^{5

3}, Suzanne Tavitian¹, Lucie Obéric¹, Jacques Izopet^{2

3

4}, Guillaume Martin-Blondel^{6

3

4}, Loic Ysebaert^{1

3

7}

Affiliations

¹ Hematology Department, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
² Laboratory of Virology, CHU Purpan, Toulouse, France.
³ University Toulouse III-Paul Sabatier, France.
⁴ INSERM U1043 - CNRS UMR 5282, Centre de Physiopathologie Toulouse-Purpan, Toulouse, France.
⁵ Internal Medicine-Digestive Department CHU Toulouse, UMR 152 IRD Toulouse 3 University, France.
⁶ Department of Infectious and Tropical Diseases, Toulouse University Hospital, France.
⁷ INSERM U1037, Centre de Recherche en Cancérologie de Toulouse, France.

Abstract

Ibrutinib is an oral first-in-class Bruton's tyrosine kinase inhibitor approved for the therapy of various B-cell lymphoid malignancies. Among ibrutinib-related infections, viral hepatitis are poorly described. We report our single-center experience with 4 cases of chronic hepatitis E virus infection and their management with ribavirin.

Keywords: hematological malignancies; hepatitis E virus; ibrutinib; immuno-deficiency; ribavirin.